Patent Office Opposes Ruling On Ovarian Cancer Drug, Wants Stronger Obviousness Standard

 
• By Brenda Sandburg
  
Ovarian cancer
USPTO is opposed to issuing patent on method of dosing ImmunoGen's ovarian cancer drug • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Legal & IP

More from Pink Sheet